Dysregulated apoptosis plays a critical role in the development of a number of aberrant cellular processes, including tumorigenesis and chemoresistance. However, the mechanisms that govern the normal apoptotic program are not completely understood. Soluble guanylyl cyclase (sGC) and cyclic guanosine monophosphate (cGMP) promote mammalian cell viability via an unknown mechanism and p53 status is a key determinant of cell fate in human ovarian cancer cells. Whether an interaction exists between these two determinants of cell fate is unknown. We hypothesized that basal sGC activity reduces p53 content and attenuates p53-dependent apoptosis in human ovarian cancer cells. Suppression of sGC activity with the specific inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) lowered cGMP content, and increased p53 protein content and induced apoptosis in three ovarian cancer cell lines, effects which were attenuated by the cGMP analog 8-Br-cGMP and by Atrial Natriuretic Factor, an activator of particulate guanylyl cyclase, which circumvent the inhibition of sGC. ODQ prolonged p53 half-life, induced phosphorylation of p53 on Ser15, and upregulated the p53-dependent gene products p21, murine double minute-2, and the proapoptotic, p53-responsive gene product Bax. ODQ activated caspase-3, and ODQ-induced apoptosis was inhibited by overexpression of X-linked inhibitor of apoptosis Protein. Pretreatment with the specific p53 inhibitor pifithrin or downregulation of p53 using a specific small inhibitory RNA significantly attenuated ODQ-induced apoptosis. Moreover, ODQ-induced upregulation of p21 and Bax and ODQ-induced apoptosis were significantly reduced in a p53 mutant cell line relative to the wild-type parental cell line. Thus, the current study establishes that basal sGC/cGMP activity regulates p53 protein stability, content, and function, possibly by altering p53 phosphorylation and stabilization, and promotes cell survival in part through regulation of caspase-3 and p53.
Introduction
Dysregulated apoptosis contributes to the development of a number of pathologies, including cancer (Liebermann et al., 1995; Reap et al., 1995; Estevez et al., 1998; Fiscus, 2002; Fiscus et al., 2002) . Tumor growth results, in part, from an imbalance between cell proliferation and apoptosis (Kerr et al., 1994; Levine et al., 1995; Sheets and Yeh, 1997; LaCasse et al., 1998) and our laboratory has been interested in the role of dysregulated apoptosis in the regulation of cell fate in human ovarian cancer cells (Sasaki et al., 2000; Asselin et al., 2001; Fraser et al., 2003) .
Soluble guanylyl cyclase (sGC) is one of the major producers of basal cyclic guanosine monophosphate (cGMP) content in mammalian cells (Waldman and Murad, 1987; Garthwaite et al., 1995; Fiscus, 2002) , and is necessary for the survival of several cell types under normal growth conditions, as well as for protection against various apoptotic stimuli (Flamigni et al., 2001) . Our previous studies have demonstrated that the basal activities of sGC and a downstream target protein in the cGMP signalling pathway, protein kinase G (PKG), may be important for the protection of uterine epithelial cells (Chan and Fiscus, 2003) and neural cell lines (Fiscus, 2002) against spontaneous apoptosis. However, the precise mechanisms by which sGC/cGMP regulates cell fate are not known.
While p53 status is a determinant of cisplatin resistance in human ovarian cancer cells and failure to properly regulate p53 may be a contributing factor to chemoresistance (Fraser et al., 2003) , precisely how p53 is regulated in these cells is unclear. In the current study, the possibility that the constitutive presence of sGC-derived cGMP is an important negative regulator of p53 content and p53-dependent apoptosis in human ovarian cancer cells is examined. The current study demonstrates that basal sGC-derived cGMP is required for the viability of human ovarian cancer cells, likely by inhibiting the activation of execution caspases such as caspase-3. Furthermore, these findings suggest that sGC/cGMP-mediated survival of these cells proceeds, in part, by lowering basal p53 protein content and phosphorylation and p53-induced apoptosis, and that the basal activity of this pathway may alter p53 content and function by promoting p53 degradation. [1, 2, 4] oxadiazolo [4,3-a] quinoxalin-1-one) depletes cellular cGMP levels To determine whether sGC is an important regulator of cGMP content in human ovarian cancer cells, OV2008 cells were cultured for 48 h, and then treated 20 min with ODQ (0-100 mM), a potent and specific sGC inhibitor (Garthwaite et al., 1995; Moro et al., 1996; Mulsch et al., 1997; Olesen et al., 1998) . Cells were harvested and cGMP assays were performed as detailed in Materials and methods. As shown in Figure 1a , ODQ Figure 1 Depletion of cGMP and induction of apoptosis by the sGC inhibitor ODQ in human ovarian cancer cells. (a) OV2008 cells were cultured for 48 h and then treated with ODQ (0-100 mM) for 20 min. cGMP assays were performed as detailed in Materials and methods. Histogram shows mean7s.e.m. of five independent experiments. ODQ significantly reduced cGMP content overall (Po0.0001). Moreover, at 50 mM ODQ, cGMP content was reduced by >60%, compared to control (Po0.001), while at 100 mM ODQ, cGMP content was B70% lower than control cells (Po0.001). Results demonstrate that inhibition of sGC activity lowers cGMP levels, suggesting that sGC is a major regulator of basal cGMP levels in ovarian cancer cells. *Po0.05, **Po0.001, relative to untreated control cells. (b) OV2008 and A2780s human ovarian cancer cells were cultured in the presence of the soluble guanylyl cyclase (sGC) inhibitor ODQ (0-50 mM), in the presence or absence of the stable cGMP analog 8-Br-cGMP (1 mM; top panel). Histograms show mean7s.e.m. of four independent experiments. ODQ significantly increased the number of apoptotic cells in both OV2008 and A2780s cells (Po0.0001, both cell lines). Moreover, 8-Br-cGMP significantly attenuated the effects of ODQ (Po0.01, OV2008; Po0.05, A2780 s). (c) A2780s cells were cultured for 24 h in the presence of ODQ (0, 30 mM). Floating and attached cells were pooled and apoptosis was determined by TUNEL assay as described in Materials and methods. (d) A2780s cells were treated with ODQ (0, 30 mM) in the presence of Atrial Natriuretic Factor (ANF, 0-1 mM; bottom panel), an activator of particulate guanylyl cyclase. Histograms show mean7s.e.m. of five independent experiments. ANF significantly attenuated ODQ-induced apoptosis (Po0.01). Results suggest that sGC is a major regulator of basal cGMP content in ovarian cancer cells, that sGC activity is required for basal viability of human ovarian cancer cells, and that the effects of ODQ are likely mediated through the cGMP pathway. ***Po0.001, relative to equimolar ODQ, 8-Br-cGMP-treated cells; **Po0.01, relative to equimolar, 8-Br-cGMP-treated cells.
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cGMP regulates p53 and apoptosis in ovarian cancer cells M Fraser et al significantly lowered cellular cGMP levels in a concentration-dependent manner (Po0.0001). Moreover, at 50 and 100 mM, ODQ lowered cGMP content by 63 and 70%, respectively (Po0.001, relative to untreated control). Even at 30 mM, ODQ significantly reduced cGMP levels, relative to control (Po0.05). These results demonstrate that inhibition of sGC activity lowers cGMP levels and suggest that sGC is a major regulator of basal cGMP levels in ovarian cancer cells.
Induction of apoptosis by the sGC inhibitor ODQ ODQ induces apoptosis in immortalized uterine epithelial cells (Chan and Fiscus, 2003) as well as in established neural cell lines (Fiscus, 2002) , suggesting that basal levels of sGC activity are important for preventing spontaneous induction of apoptosis. However, it is unclear whether this pathway affects the viability of human ovarian cancer cells, where disruptions of apoptotic mediators is commonly observed.
To address this question, A2780s and OV2008 human ovarian cancer cell lines were incubated for 24 h in the presence or absence of ODQ (0, 30, 50 mM). DMSO was used as a control and maintained at a concentration of 0.1% (v/v) in all groups. Previous studies demonstrated that ODQ at 40 mM completely inhibited sGC activity, lowered basal levels of cGMP to one-fifth of normal levels and induced apoptosis in neural cell lines (Fiscus, 2002) . In the present study, exposure of A2780s or OV2008 cells to ODQ caused a concentration-dependent increase in apoptosis, as measured by Hoechst nuclear staining (Po0.0001; Figure 1b ). ODQ-induced apoptosis was also confirmed by TUNEL assay. As expected, ODQ (30 mM) increased the percentage of TUNELpositive (i.e. apoptotic) A2780s cells (Po0.0001), relative to DMSO control (2071.25% vs. 0.770.15%; Figure 1c ). The proapoptotic effects of ODQ were significantly attenuated by the cell-permeable, stable cGMP analog 8-Br-cGMP (OV2008, Po0.01; A2780 s, Po0.05). Furthermore, ODQ-induced apoptosis was significantly attenuated by the particulate guanylyl cyclase (pGC) activator Atrial Natriuretic Factor (ANF; Figure 1d , Po0.001, all effects), suggesting that sGC activity is required for the viability of ovarian cancer cells, and that ODQ-induced apoptosis is specific to its inhibitory effects on sGC.
ODQ activates caspase-3 and induces X-linked inhibitor of apoptosis protein (Xiap)-sensitive apoptosis Since activation of the caspase cascade is a critical event for the induction of apoptosis in mammalian cells, whether inactivation of the sGC/cGMP pathway is associated with changes in caspase-3 activity were next determined. A2780s and OV2008 cells were treated with ODQ (0, 30, 50 mM) for 24 h and p17 (active) caspase-3 content was determined by Western blotting. As shown in Figure 2a , ODQ markedly upregulated the active form of caspase-3 in a concentration-dependent manner in both cell lines, suggesting that suppression of basal sGC activity may result in increased caspase-3 activity.
X-linked inhibitor of apoptosis protein (Xiap) is a potent endogenous inhibitor of caspase-3, -7, and -9, and is a central regulator of cell fate in human ovarian cancer cells (Sasaki et al., 2000; Asselin et al., 2001; Li et al., 2001) . To determine whether ODQ-induced apoptosis is similarly regulated, Xiap was overexpressed using an adenoviral sense Xiap cDNA (Xiap-s). Cells were infected for 24 h with Xiap-s (MOI ¼ 0, 2.5, 5, 10; LacZ control), and then treated with ODQ (0, 100 mM) for a further 24 h. As shown in Figure 2b , ODQ significantly increased the percentage of apoptotic cells, relative to the untreated cells (Po0.001). However, while infection with the LacZ adenovirus had no effect on ODQ sensitivity, Xiap-s inhibited ODQ-induced apoptosis in a concentration-dependent manner (Po0.01). Overexpression of Xiap was confirmed by Western blot analysis (Figure 2b . Following 24 h of infection, the virus was removed and the cells were treated with ODQ (0, 100 mM) for a further 24 h. Overexpression of Xiap was confirmed by Western blot analysis (representative of three independent experiments). ODQ significantly induced apoptosis (Po0.001), relative to the untreated control. However, these effects were inhibited by overexpression of Xiap in a concentration-dependent manner. ***Po0.001, relative to CTL; *Po0.05, **Po0.01, relative to virus-free, ODQ-treated cells.
cGMP regulates p53 and apoptosis in ovarian cancer cells M Fraser et al apoptosis. These results demonstrate that ODQ-induced apoptosis is inhibited by Xiap, and suggest that ODQinduced apoptosis involves modulation of a Xiapregulated pathway, such as caspase-3 activation.
p53 is regulated by the sGC/cGMP pathway and is required for maximal ODQ-induced apoptosis Since p53 is an important regulator of cell fate in human ovarian cancer cells, we next examined whether ODQinduced apoptosis is associated with changes in p53 content in these cells. A2780s, OV2008, and C13* cell lines were treated with ODQ as above and p53 contents were determined by Western blotting. ODQ markedly upregulated p53 in all three cell lines (Figure 3a) , suggesting that p53 may be involved in apoptosis induced by sGC inhibition.
Furthermore, while ODQ upregulated p53 in both A2780s and OV2008 cells (30 and 50 mM, respectively), this was significantly attenuated by 8-Br-cGMP (1 mM; Figure 3b , Po0.01), suggesting that ODQ-induced upregulation of p53 and induction of apoptosis is secondary to suppression of cellular cGMP levels. 8-Br-cGMP did not have a measurable effect on basal p53 levels, suggesting that in unstressed cells, p53 levels are kept at their lowest possible levels.
To determine whether p53 is required for ODQinduced apoptosis, we treated A2780s cells with ODQ (30 mM; 24 h) in the presence of the specific p53 inhibitor pifithrin-a hydrobromide (PFT) (0-30 mM). PFT is an inhibitor of p53 transactivation and p53-dependent apoptosis, which may function by preventing the nuclear import of p53 following cell stress (Komarov et al., 1999) . This inhibitor markedly attenuates the p53-induced expression of p21 WAF1/CIP1 , and its biological effects are reversible by overexpression of p53 (Fraser et al., 2003) . As shown in Figure 4a , while ODQ significantly increased the number of apoptotic cells (Po0.0001), PFT significantly, although not completely, attenuated ODQ-induced apoptosis (Po0.01), suggesting that p53 function is, at least in part, required for ODQ-induced apoptosis. However, even at 30 mM PFT, ODQ was able to induce significant apoptosis, suggesting either that 30 mM PFT does not completely inhibit the proapoptotic effects of p53, or that ODQ may induce both p53-dependent and -independent apoptosis. Furthermore, while the inhibitory effects of PFT on p53-mediated gene transcription are well documented, it is unclear whether PFT inhibits the putative mitochondrial effects of p53 (Mihara et al., 2003) . Thus, to further examine the role of p53 in sGCmediated cell survival, we downregulated p53 by RNA interference (RNAi) in ODQ-treated A2780s cells using a p53-specific small inhibitory RNA (siRNA). The cells were transfected for 24 h, and then treated with ODQ (0, 30 mM) for a further 24 h. The p53 siRNA (50 nM) markedly lowered p53 protein content in the absence and presence of ODQ (Figure 4b ), relative to the control siRNA. Furthermore, while ODQ significantly induced apoptosis (Po0.0001), this effect was significantly, although not completely, inhibited by the p53 siRNA (Po0.05). Together, these data suggest that upregulation of p53 is, at least in part, required for ODQ-induced apoptosis and that the sGC/cGMP pathway contributes to cell survival by promoting a reduction of basal p53 content. . p53 protein content was assessed by Western blot analysis. Protein content was determined by densitometry and is shown as mean7s.e.m. of three independent experiments. ODQ significantly increased p53 content in A2780s cells by over fourfold and in OV2008 cells by greater than twofold, relative to untreated control (***Po0.001, **Po0.01). These effects were significantly attenuated by 8-Br-cGMP (Po0.05). Results suggest that p53 protein content is regulated by the sGC/ cGMP pathway. **Po0.01, relative to equimolar ODQ, CTLtreated cells. and Bax in a concentration-dependent manner in the A2780s cells, these responses were markedly attenuated in A2780cp cells, despite the high p53 content in these cells (Figure 4c ). This suggests that p53 function is markedly attenuated in the p53 mutant A2780cp cell line. Moreover, ODQinduced apoptosis was significantly attenuated in A2780cp cells, relative to A2780s cells (Po0.01), suggesting that modulation of p53-mediated apoptosis is one important mechanism by which the sGC/cGMP pathway regulates cell fate.
ODQ increases p53 stability and induces its phosphorylation on Ser 15
The mechanism by which the sGC/cGMP pathway contributes to low basal p53 content and p53-mediated apoptosis is unclear. Since p53 can be regulated by murine double minute-2 (MDM2)-mediated ubiquitination and proteasomal degradation, we next wanted to determine whether inhibition of sGC affects p53 stability. To that end, A2780s cells were 'pulsed' with Results shown as mean7s.e.m. of three independent experiments. ODQ significantly increased the number of apoptotic cells (Po0.0001). This effect was significantly, although not completely, attenuated by PFT (Po0.01). ***Po0.001, relative to equimolar PFT, ODQ-treated cells; **Po0.01, relative to equimolar PFT, ODQ-treated cells. (b) A2780s cells were transfected with a p53-specific siRNA (0, 50 nM; scrambled sequence as control) for 24 h, and subsequently treated for a further 24 h with ODQ (0, 30 mM). Protein content and extent of apoptosis were assessed as indicated above. Western blot is representative, and histogram shows mean7s.e.m., of three independent experiments. ODQ significantly increased the number of apoptotic cells (Po0.0001). This was significantly, although not completely, attenuated by downregulation of p53 using the p53 siRNA (Po0.05). (c) A2780s cells and the p53 mutant variant cell line A2780cp were cultured for 24 h in the presence of ODQ (0, 15, 30 mM). Histogram shows mean7s.e.m. of three independent experiments. ODQ significantly increased the number of apoptotic cells in both cell lines (Po0.0001). However, apoptosis was significantly, although not completely, attenuated in the p53 mutant A2780cp cell line, relative to its wild-type p53 counterpart, A2780s (Po0.0001). To confirm the lack of p53 function in the A2780cp cells, we tracked p53, Bax, and p21 WAF1/CIP1 content by Western blot analysis (representative of three independent experiments). ODQ markedly upregulated p53, p21, and Bax content in the wild-type A2780s cells. Despite the high levels of (mutant) p53 in the A2780cp cells, only minimal p21 and Bax immunoreactivity was observed in this cell line. Taken together, these data suggest that the upregulation of p53 plays a role in ODQ-induced apoptosis, and that the sGC/cGMP pathway regulates basal cell viability, at least in part, through downregulation of p53. ***Po0.001, relative to CTL0transfected, CTLtreated cells; *Po0.05, relative to p53-transfected, CTL-treated cells.
cGMP regulates p53 and apoptosis in ovarian cancer cells M Fraser et al ODQ (30 mM; DMSO control) for 6 h, followed by a 'chase' period (0-240 min) in the presence of 10 mg/ml cycloheximide (CHX) (see Materials and methods). This concentration of CHX was chosen based on previous studies performed in this cell line (Xiao et al., 2003) . Whole-cell lysates were analysed for p53 content by Western blot. Blots were exposed such that p53 content in each treatment group (i.e. ODQ vs DMSO) was determined within its linear range to avoid the possible confounding effects of ODQ-mediated p53 upregulation over the 'pulse' period. As shown in Figure 5a , in the presence of DMSO, p53 was reduced to less than half of its time zero content in o30 min post-CHX. By contrast, ODQ markedly extended p53 half-life to 120-240 min, suggesting a 4-8-fold increase in p53 half-life.
While MDM2 is a key negative regulator of p53 stability, it is also a p53-responsive gene product. Furthermore, the interaction of MDM2 with p53 is attenuated by phosphorylation of p53 on Ser15. For these reasons, an analysis of MDM2 levels may not be indicative of the role of MDM2 in p53 stabilization. To that end, we next examined the effects of ODQ on MDM2 content and p53 Ser15 phosphorylation. A2780s cells were treated with ODQ (0-30 mM, as above) and whole-cell lysates were analysed for MDM2, total p53, and phospho-p53 (Ser15). As shown in Figure 5b , ODQ upregulated p53, and p53 was phosphorylated on Ser15. Furthermore, MDM2 was also upregulated by ODQ, which was expected given its p53-responsive nature.
Taken together, these results suggest that inhibition of the sGC/cGMP pathway upregulates p53 and induces p53-dependent apoptosis via phosphorylation-dependent protein stabilization.
Discussion
The present study demonstrates that the basal activity of the sGC/cGMP pathway plays an important role in the regulation of human cancer cell viability. Furthermore, our data represent, to our knowledge, the first report that directly demonstrates that this pathway influences mammalian cell viability by regulating the stability and activation of p53 and p53-mediated apoptosis.
sGC is activated by the binding of nitric oxide (NO) to its heme moiety (Waldman and Murad, 1987) . sGC also has basal activity and contributes to most of the basal cGMP levels found in mammalian cells (Waldman and Murad, 1987; Garthwaite et al., 1995; Fiscus, 2002) . While activation of sGC and elevation of cGMP levels inhibits apoptosis in many cell types (Kim et al., 1999; Fiscus et al., 2001; Fiscus, 2002; Fiscus et al., 2002) , inhibition of basal sGC activity with specific inhibitors (e.g. ODQ) lowers basal cGMP levels and induces apoptosis (Garthwaite et al., 1995; Flamigni et al., 2001; Fiscus, 2002; Chan and Fiscus, 2003) . ODQ markedly increases caspase activity, mitochondrial cytochrome c release, reduces Bcl-2 content and Bad dephosphorylation and cell viability (Flamigni et al., 2001 ). The present study demonstrates that basal sGC activity/cGMP content is required for viability in cultured ovarian cancer cells, and, as such, provides new insight into the mechanisms by which these cells may circumvent the normal induction of apoptosis. Moreover, the current study suggests that p53 may be intimately involved in the apoptosis resulting from decreased sGC activity/ cGMP availability.
While ODQ-induced apoptosis was inhibited by both ANF, an activator of the particulate form of guanylyl cyclase (pGC), and the stable cGMP analog 8-BrcGMP, neither agent completely blocked ODQ-induced apoptosis, although both reduced the percentage of apoptotic cells by >50%. It is possible that these agents were not able to fully restore basal cGMP levels, and thus could not completely restore cGMP-dependent cell survival. Moreover, 8-Br-cGMP is relatively, but not completely, resistant to phosphodiesterase-mediated degradation. Thus, the effects of this analog may be Figure 5 sGC/cGMP regulates p53 stability and phosphorylation. (a) A2780s cells were 'pulsed' with ODQ (30 mM) or DMSO (1:1000) for 6 h. Media were removed and cells were treated with cycloheximide (10 mg/ml) for different durations as indicated. Wholecell lysates were analysed for p53 content by Western blotting. Mean p53 contents (fold of 0 h control for each treatment group) of three independent experiments is included beneath the representative Western blot. (b) A2780s cells were treated with ODQ (30 mM) or DMSO (1:1000) for 24 h, and p53, phospho-p53 (Ser15), and MDM2 contents were analysed by Western blotting. Blots shown are representative of three independent replicates. cGMP regulates p53 and apoptosis in ovarian cancer cells M Fraser et al limited by degradation. Furthermore, ANF receptor abundance in ovarian cancer cells has not been examined, and may limit the effectiveness of this activator. Xiap overexpression attenuated ODQ-induced apoptosis. Together with the finding that ODQ-induced apoptosis is associated with caspase-3 cleavage, this result suggests that ODQ-induced apoptosis may be caspase-mediated. This is consistent with previous data (Flamigni et al., 2001 ) that ODQ activates caspase-3 and -9, although an involvement of these caspases in ODQinduced apoptosis was not demonstrated. Our data suggest a functional role for these caspases in ODQinduced apoptosis, and provides evidence that Xiap is a key regulator of apoptosis in human ovarian cancer cells.
p53 regulates the expression of genes involved in DNA repair, cell cycle arrest, and apoptosis. It is upregulated during cell stress via a phosphorylationdependent process which prevents p53 degradation by its negative regulator, MDM2. Since MDM2 is a p53-responsive gene product, this system functions as a negative feedback loop, avoiding inappropriate induction of p53-mediated cell cycle arrest or apoptosis but permitting a rapid response to cell stress. Moreover, the MDM2-p53 interaction is promoted by a number of cell survival mediators (Mayo and Donner, 2001; Zhou et al., 2001; Ogawara et al., 2002) . p53 also contributes to apoptosis by a transcription-independent mechanism, likely via translocation to the mitochondria, where it binds to and inhibits the antiapoptotic Bcl-2 family members (Mihara et al., 2003; Erster et al., 2004) .
ODQ upregulated p53 in three ovarian cancer cell lines, and this was attenuated by cotreatment with 8-BrcGMP, suggesting that maintenance of low basal p53 levels is promoted by tonic sGC activation and cGMP production. 8-Br-cGMP had no effect on the basal levels of p53. This is consistent with the hypothesis that basal p53 levels are already tightly regulated, and cannot be lowered further. However, removal of basal cGMP by inhibition of sGC eliminates its tonic inhibitory effect, and p53 levels are increased. Intriguingly, ODQ upregulated p53 in the cisplatin-resistant C13* cell line. We previously showed that cisplatin does not markedly upregulate p53 in these cells (Fraser et al., 2003) , suggesting that the mechanism of p53 upregulation by ODQ is distinct from that of cisplatin. Moreover, ODQinduced apoptosis was attenuated by the specific p53 inhibitor PFT, by p53 RNAi, and in p53 mutant cells. All of these mechanisms of p53 inhibition attenuated ODQ-induced apoptosis by B50%, suggesting that while p53 contributes to ODQ-induced apoptosis, p53-independent mechanism(s) are likely involved. Since ODQ also downregulated Xiap, this may represent one of these p53-independent mechanisms. This aspect is currently under investigation.
Thus, our study provides the first direct evidence that the sGC/cGMP pathway can regulate apoptosis, in part, via regulation of p53 content/function. While 8-Br-cGMP downregulates p53 following treatment of macrophages with oxidized LDL (OxLDL) (Heinloth et al., 2002) , the mechanism by which this occurs is not known. Moreover, Heinloth et al did not examine if p53 downregulation was involved in cGMP-mediated cell survival. In the current study, we demonstrate that inactivation of sGC/cGMP signalling by ODQ treatment increases p53 stability, up-regulates p53 and p53-dependent apoptosis. Interestingly, ODQ also induced the phosphorylation of p53 on Ser15, a residue that lies adjacent to the MDM2-binding site. It is required for p53 stabilization and activation following cell stress and is a determinant of p53-mediated apoptosis (Shieh et al., 1997; Siliciano et al., 1997; Ashcroft et al., 1999; Unger et al., 1999; Persons et al., 2000) . Since ODQ also upregulated MDM2, it is possible that depletion of sGC-derived cGMP results in phosphorylation-dependent attenuation of MDM2-mediated p53 degradation. It is also possible that sGC-mediated cell survival results from cGMP-dependent inhibition of another kinase targeting p53. Future studies will clarify the mechanism by which the sGC/cGMP pathway enhances p53 stability. Panahian et al. (1999) demonstrated that overexpression of heme oxygenase-1 (HO-1) facilitates neuroprotection, an effect associated with cGMP upregulation and inhibition of p53 nuclear localization. Moreover, HO-1 colocalizes with p53 in the cytoplasm of motor neurons below the level of injury and with cGMP in the nucleus of injured cells (Panahian and Maines, 2001 ). However, these results do not directly implicate cGMP as a regulator of cell survival, or as a regulator of p53. In addition, although NO-induced apoptosis is associated with an upregulation of p53 and Bax, these responses were cGMP-independent (Chen et al., 2001) . Thus, while some correlative evidence exists to suggest a link between cGMP and p53, our report represents the first direct evidence demonstrating that the sGC/cGMP pathway facilitates cell survival by negatively regulating p53 content/function. Indeed, one previous study demonstrates that activation of the cGMP pathway upregulates p53 and induces apoptosis in rat vascular endothelial cells (Suenobu et al., 1999) . Thus, the role of the sGC/cGMP pathway as a cell fate determinant may be cell-type specific.
The Akt cell survival pathway plays an important role in regulating p53 in human ovarian cancer cells (Fraser et al., 2003) . Akt phosphorylates and activates MDM2 (Mayo and Donner, 2001; Zhou et al., 2001; Ogawara et al., 2002) and cGMP promotes Akt phosphorylation (Ciani et al., 2002; Falcone et al., 2002; Ha et al., 2003; Tejedo et al., 2004) . Thus, it is possible that ODQmediated cGMP depletion inactivates Akt, thereby attenuating the inhibitory effect of MDM2 on p53. However, we did not observe any effects of ODQ on phospho-or total Akt contents (data not shown), suggesting that the ODQ-induced apoptosis are not mediated via inactivation of Akt. It is intriguing that ODQ-induced apoptosis is significantly, although incompletely, attenuated by 8-Br-cGMP. While we cannot completely exclude the possibility that ODQ may have nonspecific actions which result in apoptosis, the finding that p53 content was returned to basal levels by cGMP regulates p53 and apoptosis in ovarian cancer cells M Fraser et al 8-Br-cGMP suggests that this effect of ODQ, and the resulting p53-mediated apoptosis, is specific to the reduction in cGMP levels.
Endogenous NO depletion upregulates p53 and sensitizes melanoma cells to cisplatin-induced apoptosis (Tang and Grimm, 2004) . Since NO functions primarily, although not exclusively (Chen et al., 2001) , through the sGC activation, reduction in NO/sGC-derived cGMP levels may have been responsible for the p53 upregulation, although this was not examined. NO promotes mammary tumor invasion and nitric oxide synthase (NOS) activity is associated with breast cancer progression (Orucevic et al., 1999; Jadeski et al., 2000; Jadeski et al., 2003) . Thus, activation of NO/cGMP may be important for tumorigenesis and cancer progression.
Moreover, the basal activity of sGC mediating the antiapoptotic effects in human ovarian cancer cells may be dependent, at least in part, on the endogenous production of NO. Although the role of endogenous NO is not yet clear, recent data from our laboratory have shown that human ovarian cancer cells express all three forms of NOS, which likely results in elevated basal sGC activity (unpublished data).
It will be of interest to study the in vivo relationship between sGC/cGMP, p53, and ovarian tumorigenesis. Little is known regarding the factors that give rise to ovarian tumors, since most are not discovered until Stage III or IV, when it is difficult to decipher the molecular origins of the tumor. It will be critical to examine whether molecular abnormalities of sGC/ cGMP are a common event in ovarian cancer, where alterations in other apoptosis-related genes and gene products (e.g. PI3K, Akt, Bcl-2, p53) are frequently observed. Intriguingly, high urinary cGMP levels correlate with poor prognosis in ovarian and other cancers (Luesley et al., 1986; Luesley et al., 1987; Turner et al., 1982a, b) , although if the cGMP is derived from the tumor and plays a causative role in ovarian tumorigenesis and therapeutic response remains unclear.
In summary, our findings provide a new concept for the regulation of apoptosis in ovarian cancer cells and of ovarian tumor growth, showing a potential link between the antiapoptotic effects of the sGC/cGMP signalling pathway and the regulation of p53, an important regulator of tumorigenesis and chemotherapeutic response.
Materials and methods
Reagents
Hoechst 33258, phenylmethylsulfonyl fluoride (PMSF), sodium orthovanadate (Na 3 VO 4 ), aprotinin, and cycloheximide were purchased from Sigma (St Louis, MO, USA). Mouse monoclonal anti-p53 antibodies, clone 80 and clone DO-1, were purchased from Transduction Laboratories, Inc. (San Diego, CA, USA) and Santa Cruz Biotechnologies (Santa Cruz, CA, USA), respectively. Mouse monoclonal Bax antibody (clone 2D2) was from Santa Cruz Biotechnologies. Mouse monoclonal anti-p21 (clone DCS60), rabbit anticaspase-3 (cleaved fragment), mouse anti-phospho-p53 (Ser15), and p53 siRNA were from Cell Signaling Technology, Cell lines and culture All cell lines were maintained at 371C and in an atmosphere of 5% CO 2 /95% air. Wild-type p53, cisplatin-sensitive A2780s human ovarian cancer cells, and the mutant p53, cisplatinresistant counterpart cell line A2780cp were maintained in Dulbecco's modified Eagle's medium (DMEM)/F12 medium. OV2008 and C13* human ovarian cancer cells were maintained in RPMI 1640 medium. All media were supplemented with fetal bovine serum (10%), streptomycin (50 g/ml), penicillin (50 U/ml), fungizone (0.625 g/ml; Life Technologies, Inc., BRL, Carlsbad, CA, USA), and nonessential amino acids (1%), as previously reported (Fraser et al., 2003) . Cells were plated at a density of 5 Â 10 4 cells/cm 2 in six-well plates 18 h prior to experimental treatments. At the time of treatment, the cells were p85% confluent.
Hoechst 33258 staining
At the end of the culture period, cells attached to the growth surface were removed by trypsin treatment (trypsin (0.05%), EDTA (0.53 mM); 371C, 1 min). Attached and floating cells were pooled, pelleted by centrifugation, and resuspended in phosphate-buffered formalin (10%) containing Hoechst 33258 (12.5 ng/ml). Cells were spotted onto slides for microscopy. Nuclear staining was observed and photographed using a Zeiss fluorescence microscope (magnification Â 400). Cells with typical apoptotic nuclear morphology (nuclear shrinkage, condensation, and fragmentation) were identified and counted as previously reported (Sasaki et al., 2000 (Sasaki et al., , 2002 Asselin et al., 2001; Fraser et al., 2003) , using randomly selected fields. A minimum of 200 cells were counted in each treatment group. The counter was 'blinded' to sample identity to avoid experimental bias.
Determination of apoptosis by TUNEL assay Apoptosis also was assessed by the TUNEL method using the In Situ Cell Death Detection Kit, TMR Red assay kit from Roche (Laval, QC, Canada), according to the manufacturer's instructions. Briefly, cells were plated as above and treated with ODQ (0, 30 mM). After 24 h of treatment, floating and attached cells were pooled and pelleted by centrifugation (5 min; 300 g) and washed 2 Â in phosphate-buffered saline (PBS). The cells were fixed in 10% phosphate-buffered formalin for 1 h on ice. Fixed cells were washed in PBS and permeabilized using 0.1% Triton X-100 in 0.1% sodium citrate for 5 min. Cells were resuspended in 50 ml TUNEL reaction mixture (5 ml enzyme þ 45 ml label solution) and incubated at 371C in the dark for 1 h. Hoescht 33258 (1:1000) was added during the last 5 min to allow visualization of all nuclei under florescent microscopy. Cells were washed 2 Â in PBS and then plated on microscope slides and visualized by florescence cGMP assay cGMP contents were determined using Enzyme Immunoassay Kits (Direct Cyclic GMP) from Assay Designs, Inc. (Ann Arbor, MI, USA). The cells were plated onto 100 mm plates and after 2 days, experiments were performed to determine the cGMP depletion effects of ODQ. Each plate represented approximately 7.5 million cells. The cells were exposed to ODQ at 10, 30, 50, and 100 mM for 20 min, followed by rapid removal of media, rapid washing of the cells with PBS and addition of 1.5 ml of ice-cold 0.1 N HCl. The cells (with the HCl cell-lysis solution) were set on ice for 10 min, followed by scraping the cells from the plate and transferring the samples to microfuge tubes. The cell lysates were centrifuged at 600 g at room temperature and the supernatant fractions collected for cGMP analysis. Both the samples (200 ml) and the standards (200 ml, also prepared in the same 0.1 N HCl solution) were acetylated (as described in the protocol of the kits) in order to increase the sensitivity of the assay for cGMP measurement. Two aliquots (100 ml each) of the samples and standards were pipeted into the wells of a 96-well tray (provided in the kits). The addition of the antibody (specific for cGMP) and other reagents were added as described in the protocol of the kits. To increase the accuracy of the measurements of cGMP in samples with low cGMP content (i.e. ODQ-treated cells), we added two additional low-concentration standards (4 and 2 fmoles/well). The number of cells in the 100 mm dish was determined by counting cells with a hemocytometer. cGMP contents are reported as fmol/million cells.
Protein extraction and Western blot analysis
Cells were pelleted and lysed in ice-cold lysis buffer (pH 7.4) containing 50 mM HEPES, 150 mM NaCl, 1.5 mM MgCl 2 , 1 mM EGTA, 100 mM NaF, 10 mM NaPPi, 10% glycerol, and 1% Triton X-100. Protease inhibitors PMSF (1 mM) and aprotonin (10 g/l), as well as 1 mM Na 3 VO 4 were added to the lysis buffer freshly. Cell lysates were sonicated briefly (5 s/ cycle, 3 cycles; 01C). The sonicates were incubated on ice for 1 h and pelleted by centrifugation (15 000 g; 20 min). The supernatant was taken as whole-cell lysate and stored at À201C for subsequent analyses. Protein concentration was determined using Bio-Rad DC protein assay kit. Equal amounts of proteins (30-70 mg) were loaded and resolved by 10% SDS-PAGE and electro-transferred (30 V, 16 h) onto nitrocellulose membranes (Bio-Rad). Membranes were blocked (room temperature, 1 h) with 5% Blotto (Tris-HCl (10 mM; pH 8.0), NaCl (150 mM), Tween 20 (0.05%, v/v; TBSTween 20) containing skim milk (5%; w/v)), then incubated overnight with primary antibodies (p53 (1:1000, Clones 80 and DO-1), p21 (1:1000), Xiap (1:2000) , cleaved caspase-3 (1:1000), or GAPDH (1:30,000)), and subsequently with the appropriate horseradish peroxidase (HRP)-conjugated secondary antibody (1:2000 in 5% Blotto; room temperature, 1 h; 1:20 000 for GAPDH). Peroxidase activity was visualized with an enhanced chemiluminescence (ECL) kit (Amersham Pharmacia Biotech, Arlington Heights, IL, USA) after three washes (15 min/wash) with TBS-Tween 20. Signal intensity was determined densitometrically using Scion Image software, version 4.02 from Scion Corporation (Frederick, MD, USA). Even loading between lanes was determined using Ponceau-S stain and by densitometry of the anti-GAPDH blots.
p53 half-life determination After 18 h of plating, culture medium was removed and replaced with serum-free medium containing ODQ (30 mM) or DMSO (1:2000) and then cells were returned to the incubator for 6 h. The medium was then removed, the cells were washed two times with serum-free medium and fresh medium was added containing 10 mg/ml cycloheximide. Cells were harvested at various time points following cycloheximide treatment (0, 30, 60, 120, 240 min) . Whole-cell lysates were obtained and p53 content was analysed by Western blot. Blots were differentially exposed such that the signal was in the linear range for both treatment groups (ODQ vs DMSO).
Adenoviral infection
After 18 h of plating (10 6 cells/60-mm culture dish), cells were infected with adenoviral sense Xiap (Xiap-s) or LacZ cDNA at various multiplicities of infection (MOI) as indicated in the text as previously described (Li et al., 2001) . Adenovirus infection efficiency at MOI of 5, as determined by an X-gal staining assay against LacZ construct infected cells, was >90%. Xiap overexpression was confirmed by Western blot analysis.
RNA interference
At 18 h after plating, 6 ml of transfection reagent was added to 244 ml of DMEM/F12 without serum. The mixture was vortexed and incubated for 5 min at room temperature. Following incubation, 7.5 ml of 10 mM stock siRNA construct was added. The mixture was incubated at room temperature for a further 15 min. During this period, the culture media were removed from the cells and the cells were washed once with PBS. The siRNA mixture was added in single drops to each well to ensure maximal coverage, and an additional 1250 ml of complete (10% FBS) media were added. The cells were returned to the incubator and the media were removed 6 h later and replaced with fresh, complete media for the duration of the culture (24 h). Downregulation was confirmed by Western blot analysis.
Statistical analysis
Results are expressed as the mean7s.e.m. of at least three independent experiments. Statistical analysis was carried out by one-or two-way ANOVA or by Student's t-test (where appropriate) using PRISM software (Version 3.0; GraphPad, San Diego, CA, USA). Differences between multiple experimental groups were determined by the Bonferroni post hoc test. Statistical significance was inferred at **Po0.05.
Abbreviations sGC, soluble guanylyl cyclase; pGC, particulate guanylyl cyclase; cGMP, cyclic guanosine monophosphate; PKG, protein kinase G; ODQ, 1H-[1,2,4]oxadiazolo[43-a]quinoxalin-1-one; IAP, inhibitor of apoptosis protein; GAPDH, glyceraldehyde phosphate dehydrogenase; BNP, brain natriuretic peptide; ANF, atrial natriuretic factor; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; PMSF, phenylmethylsulfonyl fluoride; RNAi, RNA interference; siRNA, small inhibitory RNA; DMEM, Dulbecco's modified Eagle's medium; ECL, enhanced chemiluminescence; PFT, pifithrin-a hydrobromide; PBS, phosphate-buffered saline; Xiap, X-linked inhibitor of apoptosis protein; Xiap-s, adenoviral Xiap sense cDNA; ROS, reactive oxygen species; MDM2, murine double minute-2; NO, nitric oxide; CHX, cycloheximide.
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